Loading
Sections

Skip to content. | Skip to navigation

Cell & Molecular Physiology

111 Mason Farm Road
5200 Medical Biomolecular Research Building
CB 7545 Chapel Hill, NC 27599-7545

tel. (919) 966-5241
fax (919) 966-6927

 
You are here: Home > News > Potential treatment strategy for Angelman syndrome identified by Philpot, Zylka and Roth

Potential treatment strategy for Angelman syndrome identified by Philpot, Zylka and Roth

— filed under: ,

December 2011 - Collaborators Ben Philpot, Mark Zylka and Bryan Roth identify compounds that cause the dormant Ube3a gene to be expressed.

Potential treatment strategy for Angelman syndrome identified by Philpot, Zylka and Roth

At top, a mouse brain showing flourescent expression of the UBE3A gene, and below, lack of expression when the maternal copy of the gene is missing.

December 2011 - An interdisciplinary team of UNC scientists say they have found a way to “awaken” the paternal allele of Ube3a, which could lead to a potential treatment strategy for Angelman syndrome (AS). Their results were published online by the journal Nature. Read the complete UNC School of Medicine news release >>

Simons Foundation Autism Research Institute news release >>